What is HC Wainwright’s Estimate for VolitionRx Q1 Earnings?

VolitionRx Limited (NYSE:VNRX) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of VolitionRx in a note issued to investors on Tuesday, April 8th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of ($0.06) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for VolitionRx’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for VolitionRx’s Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.09 EPS, FY2025 earnings at ($0.04) EPS and FY2026 earnings at $0.01 EPS.

VNRX has been the subject of a number of other research reports. D. Boral Capital restated a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a research report on Monday, March 31st. StockNews.com initiated coverage on shares of VolitionRx in a research report on Saturday, April 5th. They issued a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, VolitionRx presently has an average rating of “Hold” and a consensus target price of $3.33.

VolitionRx Price Performance

Shares of VNRX opened at $0.49 on Wednesday. The firm has a market cap of $47.69 million, a P/E ratio of -1.37 and a beta of 1.15. The company has a 50 day simple moving average of $0.57 and a two-hundred day simple moving average of $0.63. VolitionRx has a 1 year low of $0.42 and a 1 year high of $1.02.

Institutional Investors Weigh In On VolitionRx

A number of institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after acquiring an additional 95,900 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in VolitionRx during the 4th quarter worth about $29,000. Northern Trust Corp raised its position in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares in the last quarter. Lagoda Investment Management L.P. increased its holdings in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in shares of VolitionRx in the fourth quarter worth about $36,000. Institutional investors own 8.09% of the company’s stock.

Insider Buying and Selling at VolitionRx

In other VolitionRx news, CEO Cameron John Reynolds acquired 181,818 shares of VolitionRx stock in a transaction that occurred on Wednesday, March 26th. The stock was bought at an average price of $0.55 per share, with a total value of $99,999.90. Following the completion of the purchase, the chief executive officer now directly owns 2,299,222 shares of the company’s stock, valued at approximately $1,264,572.10. This represents a 8.59 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.80% of the stock is currently owned by corporate insiders.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.